COVID-19 Vaccination Tracker: Daily Rates, Statistics & Updates
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Covid-19 Vaccination Tracker

Latest news, statistics, daily rates and updates

Last updated 23 June, 2021 10:30 CEST

As the coronavirus vaccine rolls out across the globe, our world Covid-19 vaccine tracker will help you discover the latest Covid-19 updates and live tracking of vaccine development and administration.

You can explore our data and find insights into Covid-19 vaccine clinical trials, country-level vaccination statistics, the impact of vaccination on infection and death rates, and all the latest news and information on the Covid-19 vaccination.

Number of vaccine doses administered globally

2,789,178,281

+43,273,154 reported yesterday

Number of fully vaccinated globally

797,635,144

+6,836,664 reported yesterday

Number of countries with a vaccination programme

217

+2 reported yesterday

Fully vaccinated global population

10.5%

+0.9% reported yesterday

Coronavirus vaccine roll out statistics by country

Public health authorities across the globe have been mobilising to deliver the biggest ever vaccination programme to battle Covid-19. How many people have received the Covid-19 vaccine? We bring you the latest Covid-19 vaccine numbers, including daily Covid-19 vaccine rates per country. Track worldwide Covid-19 vaccine rates with Pharmaceutical Technology and GlobalData.

Some countries have made a fast start with their vaccination efforts. By the end of January, Israel had successfully vaccinated 3 million people with the first dose. While the US may have had a slow start, President Biden has put the vaccination programme at the forefront of his first 100 days agenda. View the latest Covid-19 Vaccine Statistics below.

Country Doses Administered Doses per 1000 Fully Vaccinated Population (%) Vaccine being used in a country
World 2,789,178,281 367.3 10.5%
United States 319,872,053 977.7 46.1% Johnson&Johnson, Moderna, Pfizer/BioNTech
India 293,370,338 216.9 3.8% Covaxin, Oxford/AstraZeneca
Brazil 91,593,968 437.3 11.7% Oxford / AstraZeneca, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
United Kingdom 74,638,083 1,122.6 47.4% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Germany 69,516,383 838.3 33.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Italy 47,722,029 789.7 27.5% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Turkey 44,951,168 546.1 17.8% Pfizer/BioNTech, Sinovac
France 43,803,521 653.9 21% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Indonesia 36,998,897 138.2 4.7% Oxford/AstraZeneca, Sinovac
Mexico 36,983,641 293.1 11.8% CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Russia 36,044,137 247.0 10.7% EpiVacCorona, Sputnik V
Japan 35,788,723 282.8 8.7% Moderna, Pfizer/BioNTech
Canada 33,585,366 906.3 22.3% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Spain 32,282,553 690.9 26.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Poland 27,467,853 723.2 31.4% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Chile 20,403,835 1,089.4 48% CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Argentina 18,646,784 419.1 8.5% Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
South Korea 18,438,254 357.1 8.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Morocco 18,251,766 506.6 23.8% Oxford/AstraZeneca, Sinopharm, Sinopharm/Beijing
Colombia 15,298,930 308.1 10% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
United Arab Emirates 14,735,666 1,495.9 39% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V
Netherlands 13,734,246 797.1 29.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Pakistan 13,484,364 63.5 1.7% CanSino, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Israel 10,671,175 1,201.2 58% Moderna, Pfizer/BioNTech
Bangladesh 10,082,705 62.5 2.6% BBIBP, CorV, Oxford/AstraZeneca, Pfizer/BioNTech
Belgium 9,748,714 853.5 31.1% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Hungary 9,424,351 964.7 47.7% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Romania 8,756,809 449.7 22.4% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Philippines 8,407,342 78.8 1.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Portugal 7,774,300 756.1 29.3% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Greece 7,722,093 719.8 31% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Czechia 7,570,988 712.5 26.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Thailand 7,219,668 104.0 2.8% Oxford/AstraZeneca, Sinovac
Dominican Republic 7,172,478 674.9 24% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Austria 7,125,249 805.4 30.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Sweden 7,099,237 697.2 26% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Australia 6,860,276 274.5 4.4% Oxford/AstraZeneca, Pfizer/BioNTech
Cambodia 6,378,584 392.5 17% Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac
Malaysia 6,301,727 195.5 5.4% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Switzerland 5,785,134 679.3 26% Moderna, Pfizer/BioNTech
Peru 5,153,895 161.1 5.5% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Serbia 5,146,241 737.1 35.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Kazakhstan 4,611,224 252.3 9.6% QazVac, Sinopharm/HayatVax, Sputnik V
Iran 4,553,653 54.2 0.8% BBIBP, CorV, Covaxin, Oxford/AstraZeneca, Sputnik V
Denmark 4,180,186 721.0 28.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Finland 4,011,742 727.0 16% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Egypt 4,010,467 39.2 0.7% BBIBP, CorV, Oxford/AstraZeneca, Sinopharm, Sinovac, Sputnik V
Uruguay 3,660,589 1,061.3 43.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Norway 3,656,752 688.1 27.5% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Mongolia 3,645,291 1,149.9 54.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Singapore 3,407,068 604.2 25.6% Moderna, Pfizer/BioNTech
Slovakia 3,399,122 624.0 26.1% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Hong Kong 3,348,198 442.9 17.5% Pfizer/BioNTech, Sinovac
Sri Lanka 3,324,349 153.4 3.9% Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Cuba 3,272,579 288.6 3.6% Abdala, Soberana02
Nepal 3,231,849 115.1 2.6% Oxford/AstraZeneca, Sinopharm/Beijing
Jordan 3,197,278 321.1 10.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Ireland 3,100,000 638.7 6.7% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Kuwait 3,100,000 749.3 0.9% Pfizer/BioNTech
Azerbaijan 3,080,340 309.8 10.9% Oxford/AstraZeneca, Sinovac, Sputnik V
Qatar 2,926,066 1,051.9 46.4% Moderna, Pfizer/BioNTech
Ecuador 2,788,245 163.2 5.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Vietnam 2,626,337 27.5 0.1% Oxford/AstraZeneca
El Salvador 2,586,522 402.8 16.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Croatia 2,379,658 581.9 22.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Costa Rica 2,331,030 466.3 15.9% Oxford/AstraZeneca, Pfizer/BioNTech
Bolivia 2,231,841 196.6 5.2% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Ukraine 2,229,165 50.0 1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Lithuania 2,160,457 774.5 33.7% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Nigeria 2,030,063 10.4 0% Oxford/AstraZeneca
Bahrain 1,978,826 1,260.8 59.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
South Africa 1,871,987 32.4 1.1% Johnson&Johnson, Pfizer/BioNTech
Taiwan 1,746,130 74.0 0.1% Moderna, Oxford/AstraZeneca
Bulgaria 1,695,298 241.4 10.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Uzbekistan 1,642,744 49.8 1.4% Dimer, Oxford/AstraZeneca, RBD, Sputnik V
Tunisia 1,583,153 136.9 3.6% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Panama 1,441,439 345.1 11.7% Oxford/AstraZeneca, Pfizer/BioNTech
Slovenia 1,413,358 683.6 29.4% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Angola 1,380,174 44.8 1.7% Oxford/AstraZeneca
Venezuela 1,302,992 45.1 0.8% BBIBP, CorV, Sputnik V
Ghana 1,232,876 41.4 1.3% Oxford/AstraZeneca, Sputnik V
Kenya 1,190,889 23.2 0.4% Oxford/AstraZeneca, Sputnik V
Laos 1,183,137 162.6 6.1% Sinopharm/Beijing, Sputnik V
Lebanon 1,175,505 171.6 5.6% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Zimbabwe 1,146,378 79.4 3.1% Sinopharm/Beijing
Latvia 1,092,435 567.0 26% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
New Zealand 1,019,364 208.7 7.8% Pfizer/BioNTech
Estonia 914,509 692.3 27.7% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Albania 890,052 310.5 12.9% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Afghanistan 765,890 20.6 0.5% BBIBP, CorV, Oxford/AstraZeneca, Pfizer/BioNTech
Palestine 757,974 148.6 5.8% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Cyprus 728,458 575.1 22.8% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Belarus 685,500 72.3 2.9% BBIBP, CorV, Sputnik V
Paraguay 662,804 95.3 3.5% Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Guatemala 661,648 38.4 0.8% Moderna, Oxford/AstraZeneca
Moldova 655,537 184.9 6.9% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Senegal 632,648 39.9 1% BBIBP, CorV, Oxford/AstraZeneca, Sinopharm/Beijing
Malta 631,446 1,305.9 60% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Iraq 613,840 16.0 0.4% BBIBP, CorV, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Sudan 610,924 14.6 0.3% BBIBP, CorV, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Oman 605,845 125.4 3.5% Oxford/AstraZeneca, Pfizer/BioNTech
Mauritius 598,863 473.3 17.3% BBIBP, CorV, Covaxin, Oxford/AstraZeneca
Luxembourg 491,716 809.1 31.7% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Maldives 489,415 949.0 34.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Honduras 488,859 51.0 0.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Sputnik V
North Macedonia 482,058 231.4 9.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Malawi 425,051 23.4 0.2% Oxford/AstraZeneca
Mozambique 394,930 13.4 0.3% Oxford/AstraZeneca, Sinopharm/Beijing
Guinea 384,974 31.0 0.8% Sputnik V
Iceland 368,066 1,041.0 47.1% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Togo 347,246 44.0 1% Oxford/AstraZeneca
Georgia 322,976 86.6 2.3% Oxford/AstraZeneca
Bosnia and Herzegovina 315,780 95.0 1.9% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Macao 307,506 486.8 14.5% Pfizer/BioNTech, Sinopharm/Beijing
Guyana 294,053 377.5 10.2% Oxford/AstraZeneca, Sputnik V
Montenegro 279,639 449.3 21.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Fiji 274,008 310.1 2% Oxford/AstraZeneca
Equatorial Guinea 247,228 188.9 7.5% Sinopharm/Beijing
Trinidad and Tobago 235,400 169.4 3.7% Oxford/AstraZeneca
Niger 186,207 8.3 0.1% BBIBP, CorV, Oxford/AstraZeneca
Suriname 182,331 316.6 5.7% Oxford/AstraZeneca
Somalia 178,264 11.9 0.3% BBIBP, CorV, Oxford/AstraZeneca, Sinovac
Mali 176,038 9.2 0.2% Oxford/AstraZeneca
Kyrgyzstan 173,700 27.5 1.2% Sinopharm/Beijing, Sputnik V
Curacao 165,266 1,033.9 48.2% Moderna, Pfizer/BioNTech
Zambia 147,115 8.5 0% Oxford/AstraZeneca, Sinopharm/Beijing
Barbados 147,036 513.0 21.6% Oxford/AstraZeneca
Seychelles 137,676 1,422.8 69.3% Oxford/AstraZeneca, Sinopharm/Beijing
Mauritania 136,003 30.9 0.2% BBIBP, CorV, Oxford/AstraZeneca, Sinopharm/Beijing
Kosovo 133,868 72.5 1% Oxford/AstraZeneca
Northern Cyprus 129,743 348.3 14.6% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
French Polynesia 125,484 451.9 20.7% Oxford/AstraZeneca
Aruba 124,856 1,179.6 54.5% Pfizer/BioNTech
Namibia 124,460 50.8 0.8% Oxford/AstraZeneca, Sinopharm/Beijing
New Caledonia 104,683 359.3 16.5% Pfizer/BioNTech
Isle of Man 98,546 1,172.1 43% Oxford/AstraZeneca, Pfizer/BioNTech
Sierra Leone 97,315 12.7 0.2% BBIBP, CorV, Oxford/AstraZeneca
Cameroon 97,245 3.9 0.1% BBIBP, CorV, Oxford/AstraZeneca
Jersey 94,574 877.3 36.1% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Cayman Islands 89,619 1,396.5 65.4% Oxford/AstraZeneca, Pfizer/BioNTech
Comoros 84,360 101.4 5% Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Gibraltar 77,969 2,312.4 115.1% Pfizer/BioNTech
Guernsey 77,881 1,242.0 21.7% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Belize 71,916 187.7 2.8% Oxford/AstraZeneca, Sinopharm/Beijing
Liberia 68,821 14.3 0% Oxford/AstraZeneca
Congo 67,511 0.8 0% BBIBP, CorV, Moderna, Oxford/AstraZeneca, Sputnik V
Bermuda 66,564 1,040.6 48.9% Pfizer/BioNTech
Cape Verde 63,606 114.4 0.5% Oxford/AstraZeneca, Pfizer/BioNTech
Brunei 62,343 134.2 2.5% Oxford/AstraZeneca, Sinopharm/Beijing
Antigua and Barbuda 58,074 603.1 24.3% Oxford/AstraZeneca
Saint Lucia 51,563 283.5 11.7% Oxford/AstraZeneca
Samoa 45,178 230.3 0.6% Oxford/AstraZeneca
San Marino 44,379 1,313.6 66% Pfizer/BioNTech, Sputnik V
Eswatini 44,305 39.0 0.7% Oxford/AstraZeneca
Central African Republic 42,644 9.1 0% Covaxin, Oxford/AstraZeneca
Turkmenistan 41,993 7.0 0.2% EpiVacCorona, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Gabon 41,737 19.7 0.6% Sinopharm/Beijing
Gambia 40,810 17.9 0.5% Oxford/AstraZeneca, Sinopharm/Beijing
Dominica 37,126 518.3 24.2% Oxford/AstraZeneca
Lesotho 36,759 17.4 0% Oxford/AstraZeneca
Monaco 33,965 878.1 39.1% Pfizer/BioNTech
Greenland 33,425 596.6 18.6% Moderna, Pfizer/BioNTech
Saint Kitts and Nevis 31,054 583.5 18% Oxford/AstraZeneca
Tonga 29,980 283.6 1.3% Oxford/AstraZeneca
South Sudan 29,410 2.7 0% Oxford/AstraZeneca
Benin 26,624 2.3 0% Oxford/AstraZeneca, Sinovac
Liechtenstein 25,780 680.0 27.5% Moderna, Pfizer/BioNTech
Sint Maarten (Dutch part) 24,634 605.9 24.5% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Sao Tome and Principe 23,918 113.3 5.5% Oxford/AstraZeneca
Solomon Islands 21,469 32.9 0.5% Oxford/AstraZeneca
Andorra 19,064 247.6 1.6% Oxford/AstraZeneca, Pfizer/BioNTech
Anguilla 13,235 732.6 24.5% Oxford/AstraZeneca
Wallis and Futuna 8,834 558.8 27.2% Oxford/AstraZeneca
Bonaire Sint Eustatius and Saba 7,391 275.7 6.2% Moderna, Pfizer/BioNTech
Falkland Islands 4,322 1,070.1 42.5% Oxford/AstraZeneca
Montserrat 1,306 243.7 3.6% Oxford/AstraZeneca

World map of vaccinations – total doses and fully vaccinated

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine numbers as they happen each day.

Total doses tracks the number of vaccine doses applied, whether they be the first or second of the two dose treatments or the one dose vaccine. Fully vaccinated captures the combined number of people to have received either both shots of a two-stage vaccine or the one-shot vaccine. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

The first ever dose of Covid-19 vaccine was administered in the UK in December 2020, and the global vaccination effort has fast expanded with most countries beginning to start their vaccination programmes.

However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out. View the Covid-19 vaccination world map below.

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine first dose and second dose numbers as they happen each day. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

With the worldwide first dose vaccination administered in the UK in December 2020, the global Covid-19 vaccination effort has fast expanded with most countries beginning to start their vaccination programmes. However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

Global Covid-19 vaccinations

This Covid-19 vaccination chart shows a steadily growing Covid-19 vaccination rate globally since January 2021, the first full month of the global Covid-19 vaccination drive. For more details also see GlobalData’s intelligence on Covid-19 vaccinations per country.

Country-level Covid-19 vaccination

With Israel having a head start with Covid-19 vaccine numbers, many countries are stepping up their effort to battle new cases and death rates with fast Covid-19 vaccine roll-outs.

Vaccines administered

Vaccine doses per 1,000 people

Fully vaccinated population

Leading vaccine candidates and current status

At the start of February nine approved Covid-19 vaccines were being used globally to fight the rising global death rate from Covid-19. The Janssen vaccine is likely to achieve imminent approval and there are almost 50 other Covid-19 vaccines still in development. Some might never progress to regulatory approval, but with new variants of Covid-19 spreading fast the race for the most effective and affordable Covid-19 vaccine is still on. Follow GlobalData’s tracker on Covid-19 vaccine initiatives and Covid-19 vaccine trials here:

Progress: Trial Results expected Awaiting approval Available to public
Trial size Doses requierd Storage temperature Efficacy Number of countries approved

Pfizer/BioNTech 46,331 2 8°C to -90°C 95.0% 33

mRNA vaccine, first to demonstrate positive Phase 3 results. Impressive efficacy of 95% in prevention of Covid-19, with a single drawback of requiring unusually cold (-70 degrees F) conditions for storage and transportation.

Trial Start Date - 29 April 2020
Result Publication Date - 18 November 2020
10 May, 2021: Emergency Use Authorization given by US
7 May, 2021: Emergency Use Authorization given by Sri Lanka
6 May, 2021: Emergency Use Authorization given by Canada
16 Mar, 2021: Emergency Use Authorization given by South Africa
15 Mar, 2021: Emergency Use Authorization given by Maldives
5 Mar, 2021: Emergency Use Authorization given by Republic of Korea
1 Mar,2021: Complete Approval given by Denmark
23 Feb,2021: Complete Approval given by Brazil
14 Feb,2021: Complete Approval given by Japan
10 Feb, 2021: Emergency Use Authorization given by New Zealand
2 Feb, 2021: Emergency Use Authorization given by Peru
25 Jan, 2021: Complete Approval given by Australia
25 Jan, 2021: Emergency Use Authorization given by Hong Kong
13 Jan, 2021: Emergency Use Authorization given by Philippines
11 Jan, 2021: Emergency Use Authorization given by Mongolia
6 Jan, 2021: Emergency Use Authorization given by Colombia
27 Dec, 2020: Emergency Use Authorization given by Iraq
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Complete Approval given by EU
21 Dec, 2020: Emergency Use Authorization given by Qatar
19 Dec, 2020: Complete Approval given by Switzerland
17 Dec, 2020: Emergency Use Authorization given by Ecuador
16 Dec, 2020: Emergency Use Authorization given by Panama
16 Dec, 2020: Emergency Use Authorization given by Chile
16 Dec, 2020: Emergency Use Authorization given by Costa Rica
15 Dec, 2020: Emergency Use Authorization given by Oman
15 Dec, 2020: Emergency Use Authorization given by Jordan
14 Dec, 2020: Emergency Use Authorization given by Singapore
13 Dec, 2020: Emergency Use Authorization given by Kuwait
12 Dec, 2020: Emergency Use Authorization given by Mexico
11 Dec, 2020: Emergency Use Authorization given by US
10 Dec, 2020: Emergency Use Authorization given by Saudia Arabia
9 Dec, 2020: Emergency Use Authorization given by Canada
4 Dec, 2020: Emergency Use Authorization given by Bahrain
2 Dec, 2020: Emergency Use Authorization given by UK
Today

Moderna 30,420 2 8°C to -20°C 94.5% 15

Like Pfizer/BioNTech’s offering, is an mRNA vaccine with a nearly identical 95% efficacy for prevention of Covid-19. Also requires freezing temperatures but does not require ultra-low temperatures as Pfizer/BioNTech’s vaccine does.

Trial Start Date - 27 July 2020
Result Publication Date - 16 November 2020
21 May, 2021: Complete Approval given by South Korea
21 May, 2021: Emergency Use Authorization given by Japan
13 May, 2021: Emergency Use Authorization given by Thailand
13 May, 2021: Emergency Use Authorization given by Philippines
30 Apr, 2021: Emergency Use Listing (EUL) given by WHO
9 Feb, 2021: Emergency Use Authorization given by Qatar
3 Feb, 2021: Emergency Use Authorization given by Singapore
12 Jan, 2021: Emergency Use Authorization given by Switzerland
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by UK
8 Jan, 2021: Emergency Use Authorization given by France
6 Jan, 2021: Complete Approval given by EU
4 Jan, 2021: Authorization to import given by Israel
23 Dec, 2020: Emergency Use Authorization given by Canada
18 Dec, 2020: Emergency Use Authorization given by US
Today

AstraZeneca Plc 24,820 2 2 - 8°C 70.4 47

Adenoviral vaccine which has produced mixed results depending on region, vaccine dosing regimen, and schedule. While overall efficacy may be lower than some competitors, protections against hospitalization and death is strong.

Trial Start Date - 28 May 2020
Result Publication Date - 08 December 2020
21 May, 2021: Emergency Use Authorization given by Japan
25 Mar, 2021: Emergency Use Authorization given by Finland
25 Mar, 2021: Emergency Use Authorization given by Iceland
18 Mar, 2021: Emergency Use Authorization given by Portugal
10 Mar, 2021: Emergency Use Authorization given by Papua New Guinea
10 Mar, 2021: Emergency Use Authorization given by Portugal
8 Mar, 2021: Emergency Use Authorization given by Indonesia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Canada
26 Feb, 2021: Emergency Use Authorization given by Costa Rica
24 Feb, 2021: Emergency Use Authorization given by Colombia
22 Feb, 2021: Emergency Use Authorization given by Ukraine
18 Feb, 2021: Emergency Use Authorization given by Saudi Arabia
18 Feb, 2021: Emergency Use Authorization given by Nigeria
17 Feb, 2021: Emergency Use Authorization given by Iran
16 Feb, 2021: Emergency Use Authorization given by Australia
15 Feb, 2021: Emergency Use Listing (EUL) given by WHO
10 Feb, 2021: Emergency Use Authorization given by South Korea
6 Feb, 2021: Complete Approval given by Spain
5 Feb, 2021: Emergency Use Authorization given by Greece
2 Feb, 2021: Complete Approval given by France
2 Feb, 2021: Complete Approval given by Sweden
1 Feb, 2021: Emergency Use Authorization given by Vietnam
1 Feb, 2021: Emergency Use Authorization given by Egypt
31 Jan, 2021: Emergency Use Authorization given by Kuwait
30 Jan, 2021: Complete Approval given by Italy
29 Jan, 2021: Complete Approval given by EU
29 Jan, 2021: Emergency Use Authorization given by Philippines
27 Jan, 2021: Emergency Use Authorization given by Chile
23 Jan, 2021: Emergency Use Authorization given by South Africa
23 Jan, 2021: Emergency Use Authorization given by Bhutan
22 Jan, 2021: Emergency Use Authorization given by Sri Lanka
21 Jan, 2021: Emergency Use Authorization given by Thailand
21 Jan, 2021: Emergency Use Authorization given by Hungary
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Brazil
17 Jan, 2021: Emergency Use Authorization given by Pakistan
15 Jan, 2021: Emergency Use Authorization given by Nepal
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by Bangladesh
6 Jan, 2021: Emergency Use Authorization given by India
6 Jan, 2021: Emergency Use Authorization given by Argentina
6 Jan, 2021: Emergency Use Authorization given by Dominican Republic
6 Jan, 2021: Emergency Use Authorization given by El Salvador
6 Jan, 2021: Emergency Use Authorization given by Mexico
6 Jan, 2021: Emergency Use Authorization given by Morocco
30 Dec, 2020: Emergency Use Authorization given by UK
Today

Novavax Inc 15,203 2 2 - 8°C 94.6% 0

Uses virus-like particles (VLPs) produced in insect cells and demonstrated nearly 90% efficacy against Covid-19 in studies conducted in the UK.

Trial Start Date - 28 September 2020
Result Publication Date - 11 March 2021
Today

Johnson & Johnson 44,325 1 2 - 8°C 66% 13

Adenoviral vaccine able to confer nearly 70% protection against all Covid-19 with a single dose. Like AstraZeneca’s vaccine, overall protection is not the highest, but offers near-complete protection against hospitalization and death. Also being tested as a two-dose regimen.

Trial Start Date - 07 September 2020
Result Publication Date - 29 January 2021
20 Apr, 2021: Emergency Use Authorization given by Philippines
07 Apr, 2021: Conditional Marketing Authorization given by South Korea
26 Mar, 2021: Emergency Use Authorization given by Colombia
25 Mar, 2021: Emergency Use Authorization given by Thiland
26 Mar, 2021: Emergency Use Authorization given by Switzerland
12 Mar, 2021: Conditional Marketing Authorization given by Italy
12 Mar, 2021: Conditional Marketing Authorization given by France
12 Mar, 2021: Emergency Use Listing (EUL) given by WHO
11 Mar, 2021: Conditional Marketing Authorization given by EU
5 Mar, 2021: Emergency Use Authorization given by Canada
27 Feb, 2021: Emergency Use Authorization given by the US
25 Feb, 2021: Emergency Use Authorization given by the US
https://www.aljazeera.com/news/2021/2/17/south-africa-begins-vaccine-rollout-through-observational-study
Today

Gamaleya 33,758 2 2 - 8°C 91.4% 68

Developed by Russia, uses two different adenoviruses, one for each of two doses, as part of a heterologous vaccination plan. Has shown excellent efficacy of just over 90% in preventing all Covid-19.

Early Approval - 12 August 2020
Trial Start Date - 07 September 2020
Result Publication Date - 14 December 2020
30 Apr, 2021: Emergency Use Authorization given by Turkey
30 Apr, 2021: Emergency Use Authorization given by Albania
27 Apr, 2021: Emergency Use Authorization given by Bangladesh
12 Apr, 2021: Emergency Use Authorization given by India
1 Apr, 2021: Emergency Use Authorization given by Panama
30 Mar, 2021: Emergency Use Authorization given by Mali
26 Mar, 2021: Emergency Use Authorization given by Antigua
26 Mar, 2021: Emergency Use Authorization given by Barbuda
23 Mar, 2021: Emergency Use Authorization given by Vietnam
22 Mar, 2021: Emergency Use Authorization given by Mauritius
19 Mar, 2021: Emergency Use Authorization given by Cameroon
19 Mar, 2021: Emergency Use Authorization given by Philippines
19 Mar, 2021: Emergency Use Authorization given by Republic of Seychelles
12 Mar, 2021: Emergency Use Authorization given by Azerbaijan
11 Mar, 2021: Emergency Use Authorization given by Namibia
10 Mar, 2021: Emergency Use Authorization given by Jordan
10 Mar, 2021: Emergency Use Authorization given by Kenya
10 Mar, 2021: Emergency Use Authorization given by Morocco
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
7 Mar, 2021: Emergency Use Authorization given by Macedonia
7 Mar, 2021: Emergency Use Authorization given by North Macedonia
4 Mar, 2021: Emergency Use Authorization given by Sri Lanka
4 Mar, 2021: Emergency Use Authorization given by Iraq
4 Mar, 2021: Emergency Use Authorization given by Laos
3 Mar, 2021: Emergency Use Authorization given by Angola
3 Mar, 2021: Emergency Use Authorization given by Djibouti
3 Mar, 2021: Emergency Use Authorization given by Republic of the Congo
1 Mar, 2021: Emergency Use Authorization given by Slovakia
26 Feb, 2021: Emergency Use Authorization given by Republic of Moldova
25 Feb, 2021: Emergency Use Authorization given by Guatemala
24 Feb, 2021: Emergency Use Authorization given by Egypt
24 Feb, 2021: Emergency Use Authorization given by Honduras
23 Feb, 2021: Emergency Use Authorization given by Kyrgyzstan
23 Feb, 2021: Emergency Use Authorization given by Guyana
20 Feb, 2021: Emergency Use Authorization given by Ghana
19 Feb, 2021: Emergency Use Authorization given by San Marino
17 Feb, 2021: Emergency Use Authorization given by Gabon
17 Feb, 2021: Emergency Use Authorization given by Uzbekistan
12 Feb, 2021: Emergency Use Authorization given by Montenegro
12 Feb, 2021: Emergency Use Authorization given by Saint Vincent and the Grenadines
10 Feb, 2021: Emergency Use Authorization given by Bahrain
9 Feb, 2021: Emergency Use Authorization given by Mongolia
9 Feb, 2021: Emergency Use Authorization given by Pakistan
9 Feb, 2021: Emergency Use Authorization given by Mongolia
6 Feb, 2021: Emergency Use Authorization given by Myanmar
6 Feb, 2021: Emergency Use Authorization given by Bosnia and Herzegovina
5 Feb, 2021: Emergency Use Authorization given by Lebanon
3 Feb, 2021: Emergency Use Authorization given by Mexico
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
1 Feb, 2021: Emergency Use Authorization given by Armenia
30 Jan, 2021: Emergency Use Authorization given by Tunisia
29 Jan, 2021: Emergency Use Authorization given by Republic of Guinea
26 Jan, 2021: Emergency Use Authorization given by Iran
21 Jan, 2021: Emergency Use Authorization given by Hungary
21 Jan, 2021: Emergency Use Authorization given by UAE
18 Jan, 2021: Emergency Use Authorization given by Turkmenistan
15 Jan, 2021: Emergency Use Authorization given by Paraguay
14 Jan, 2021: Temporary Registration given by Kazakhstan
13 Jan, 2021: Emergency Use Authorization given by Venezuela
11 Jan, 2021: Emergency Use Authorization given by Palestine
10 Jan, 2021: Emergency Use Authorization given by Algeria
6 Jan, 2021: Emergency Use Authorization given by Bolivia
31 Dec, 2020: Emergency Use Authorization given by Serbia
28 Dec, 2020: Approved by Russia for population aged 60 years and above
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Emergency Use Authorization given by Belarus
12 Aug, 2020: Complete Approval given by Russia
Today

Sinovac Biotech 29,608 2 2 - 8°C 50.7% 20

Vaccine from China, one of few vaccines using inactivated SARS-CoV-2 viruses which is a much more conventional vaccine technology than others which have demonstrated positive Phase III data.

Early Approval - 11 January 2021
Trial Start Date - 21 July 2020
Result Publication Date - 05 February 2021
27 Apr, 2021: Emergency Use Authorization given by Egypt
10 Apr, 2021: Emergency Use Authorization given by Pakistan
9 Apr, 2021: Emergency Use Authorization given by Panama
10 Mar, 2021: Complete Approval given by Ukraine
10 Mar, 2021: Emergency Use Authorization given by Zimbabwe
05 Mar, 2021: Complete Approval given by Tunisia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Hong Kong
26 Feb, 2021: Emergency Use Authorization given by Ecuador
22 Feb, 2021: Emergency Use Authorization given by Philippines
22 Feb, 2021: Emergency Use Authorization given by Thailand
13 Feb, 2021: Emergency Use Authorization given by Cambodia
11 Feb, 2021: Emergency Use Authorization given by Mexico
8 Feb, 2021: Emergency Use Authorization given by China
6 Feb, 2021: Emergency Use Authorization given by Lao People's Democratic Republic
6 Feb, 2021: Emergency Use Authorization given by Uruguay
5 Feb, 2021: Emergency Use Authorization given by Colombia
21 Jan, 2021: Emergency Use Authorization given by Chile
18 Jan, 2021: Emergency Use Authorization given by Brazil
13 Jan, 2021: Emergency Use Authorization given by Turkey
11 Jan, 2021: Emergency Use Authorization given by Indonesia
Today

Sinopharm 60,000+ 2 2 - 8°C 86.0% 20

The second inactivated vaccine, also being developed by China, has shown mixed results in Brazil, where initial efficacy was 86% based on data from the UAE, but efficacy data from Brazil were significantly lower at only 50%.

Early Approval - 10 December 2020
Trial Start Date - 16 July 2020
Result Publication Date - 31 December 2020
29 Apr, 2021: Emergency Use Authorization given by Indonesia
16 Mar, 2021: Emergency Use Authorization given by Maldives
11 Mar, 2021: Emergency Use Authorization given by Iran
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
1 Mar, 2021: Emergency Use Authorization given by Venezuela
26 Feb, 2021: Emergency Use Authorization given by Guyana
22 Feb, 2021: Emergency Use Authorization given by Argentina
18-Feb, 2021: Emergency Use Authorization given by Nepal
4 Feb, 2021: Emergency Use Authorization given by Cambodia
29 Jan, 2021: Emergency Use Authorization given by Hungary
27 Jan, 2021: Emergency Use Authorization given by Peru
24 Jan, 2021: Emergency Use Authorization given by Morocco
19 Jan, 2021: Emergency Use Authorization given by Pakistan
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Republic of Serbia
9 Jan, 2021: Emergency Use Authorization given by Jordan
4 Jan, 2021: Emergency Use Authorization given by Egypt
2 Jan, 2021: Emergency Use Authorization given by China
14 Dec, 2020: Emergency Use Authorization given by Bahrain
10 Dec, 2020: Complete Approval given by UAE
Today

CanSino Biologics 40,000 1 2 - 8°C 65.7% 5

Like Johnson & Johnson’s vaccine, this vaccine from China showed just under 70% efficacy in preventing all Covid-19 and 90% efficacy in preventing severe Covid-19 with just a single dose.

8 Apr, 2021: Emergency Use Authorization given by Chile
22 Mar, 2021: Emergency Use Authorization given by Hungary
12 Feb, 2021: Emergency Use Authorization given by Pakistan
11 Feb, 2021: Emergency Use Authorization given by Mexico
25 Jun, 2020: Military Use Authorization given by China
Trial Start Date - 15 September 2020
Today

Bharat Biotech 25,800 2 2 - 8°C 81.0% 7

Adjuvanted invactivated vaccine priduced in Vero cells and developed by India, showed 81% efficacy in preventing COVID-19 after two doses.

20 Apr, 2021: Emergency Use Authorization given by Philippines
6 Apr, 2021: Emergency Use Authorization given by Mexico
26 Mar, 2021: Complete Approval given by Mauritius
21 Mar, 2021: Emergency Use Authorization given by Nepal
04 Mar, 2021: Emergency Use Authorization given by Zimbabwe
19 Feb, 2021: Emergency Use Authorization given by Iran
3 Jan, 2021: Restricted Emergency Use Authorization given by India
Trial Start Date - 16 November 2020
Today

Covid-19 vaccine clinical trials by region

Covid-19 vaccine clinical trials by trial phase

Covid-19 vaccine clinical trials by trial status

Covid-19 - The race to herd immunity

According to the World Health Organization (WHO), "Herd Immunity, also known as population immunity, is the indirect protection from an infectious disease that happens when a population is immune either through vaccination or immunity developed through previous infection."

Herd immunity against Covid-19 has been widely debated over the past months, however WHO has admitted, "we do not have a clear understanding of the herd immunity level for Covid-19."

So, what is the herd immunity percentage for Covid-19?

In the context of Covid-19, herd immunity level is 60-70%,but could be higher if the new variants of the virus are more contagious.

The assumption should always be higher rather than lower with some recent research suggesting the number of the population that needed to be vaccinated ranged from 69-93%.

Race to herd immunity (Top 20 countries by vaccination rate)

Race to herd immunity (Leading economies)

GlobalData Reports

View More

Up Next

Receive our newsletter Sign up to our e-Newsletter here

Close